Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0644
D

Failure to Update PASARR Screening After Initiation of Psychotropic Medications

Paramount, California Survey Completed on 04-25-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that a Preadmission Screening and Resident Review (PASARR) was accurately documented for one resident. The resident was admitted with diagnoses of anxiety, depression, and post-traumatic stress disorder (PTSD). Initial PASARR Level 1 screening was completed and found negative, indicating that a Level II assessment was not required at that time. However, subsequent records showed that the resident was later prescribed paroxetine (an antidepressant) and risperidone (an antipsychotic) for their mental health conditions. Despite these new prescriptions and ongoing diagnoses, no updated PASARR Level 1 screening was completed after the initiation of these psychotropic medications. Interviews with the MDS Assistant and the DON confirmed that a new PASARR Level 1 should have been conducted when the resident began these medications. Facility policy required screening for mental disorders and referral to the appropriate authority when such conditions were identified, but this process was not followed, resulting in a deficiency.

An unhandled error has occurred. Reload 🗙